Glucose-Oxidized Low-Density Lipoproteins Enhance Insulin-Like Growth Factor I-Stimulated Smooth Muscle Cell Proliferation by Inhibiting Integrin-Associated Protein Cleavage

被引:12
作者
Allen, Lee B. [1 ]
Capps, Byron E. [1 ]
Miller, Emily C. [1 ]
Clemmons, David R. [1 ]
Maile, Laura A. [1 ]
机构
[1] Univ N Carolina, Dept Med, Div Endocrinol, Chapel Hill, NC 27599 USA
关键词
ATHEROSCLEROTIC LESIONS; ALPHA-V-BETA-3; INTEGRIN; RECEPTOR EXPRESSION; DOWN-REGULATION; BINDING DOMAIN; IGF-I; ACTIVATION; KINASE; LDL; BETA-3-SUBUNIT;
D O I
10.1210/en.2008-1090
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Prior published reports have demonstrated that glucose-oxidized low-density lipoproteins (g-OxLDL) enhance the proliferative response of vascular smooth muscle cells (SMC) to IGF-I. Our previous studies have determined that the regulation of cleavage of integrin-associated protein (IAP) by matrix-metalloprotease-2 (MMP-2) in diabetic mice in response to hyperglycemia is a key regulator of the response of SMC to IGF-I. Because chronic hyperglycemia enhances glucose-induced LDL oxidation, these studies were conducted to determine whether g-OxLDL modulates the response of SMC to IGF-I by regulating MMP-2-mediated cleavage of IAP. We determined that exposure of SMC to g-OxLDL, but not native LDL, was sufficient to facilitate an increase in cell proliferation in response to IGF-I. Exposure to an anti-CD36 antibody, which has been shown to inhibit g-OxLDL-mediated signaling, inhibited the effects of g-OxLDL on IGF-I-stimulated SMC proliferation. The effect of g-OxLDL could be attributed, in part, to an associated decrease in proteolytic cleavage of IAP leading to increase in the basal association between IAP and Src homology 2 domain-containing protein tyrosine phosphatase substrate-1, which is required for IGF-I-stimulated proliferation. The inhibitory effect of g-OxLDL on IAP cleavage appeared to be due to its ability to decrease the amount of activated MMP-2, the protease responsible for IAP cleavage. In conclusion, these data provide a molecular mechanism to explain previous studies that have reported an enhancing effect of g-OxLDL on IGF-I-stimulated SMC proliferation. (Endocrinology 150: 1321-1329, 2009)
引用
收藏
页码:1321 / 1329
页数:9
相关论文
共 43 条
[1]   Role for matrix metalloproteinase-2 in oxidized low-density lipoprotein-induced activation of the sphingomyelin/ceramide pathway and smooth muscle cell proliferation [J].
Augé, N ;
Maupas-Schwalm, F ;
Elbaz, M ;
Thiers, JC ;
Waysbort, A ;
Itohara, S ;
Krell, HW ;
Salvayre, R ;
Nègre-Salvayre, A .
CIRCULATION, 2004, 110 (05) :571-578
[2]   INDUCTION OF INSULIN-LIKE GROWTH FACTOR-I MESSENGER-RNA IN RAT AORTA AFTER BALLOON DENUDATION [J].
CERCEK, B ;
FISHBEIN, MC ;
FORRESTER, JS ;
HELFANT, RH ;
FAGIN, JA .
CIRCULATION RESEARCH, 1990, 66 (06) :1755-1760
[3]   Oxidized low density lipoprotein stimulates aortic smooth muscle cell proliferation [J].
Chatterjee, S ;
Ghosh, N .
GLYCOBIOLOGY, 1996, 6 (03) :303-311
[4]   Oxidized low density lipoproteins stimulate galactosyltransferase activity, ras activation, p(44) mitogen activated protein kinase and c-fos expression in aortic smooth muscle cells [J].
Chatterjee, S ;
Bhunia, AK ;
Snowden, A ;
Han, H .
GLYCOBIOLOGY, 1997, 7 (05) :703-710
[5]   Interaction between insulin-like growth factor-I receptor and αVβ3 integrin linked signaling pathways:: Cellular responses to changes in multiple signaling inputs [J].
Clemmons, DR ;
Maile, LA .
MOLECULAR ENDOCRINOLOGY, 2005, 19 (01) :1-11
[6]   The expression of the lectin-like oxidized low-density lipoprotein receptor (LOX-1) on human vascular smooth muscle cells and monocytes and its down-regulation by lovastatin [J].
Draude, G ;
Hrboticky, N ;
Lorenz, RL .
BIOCHEMICAL PHARMACOLOGY, 1999, 57 (04) :383-386
[7]  
ENDEMANN G, 1993, J BIOL CHEM, V268, P11811
[8]   Cooperation between low density lipoproteins and IGF-I in the promotion of mitogenesis in vascular smooth muscle cells [J].
González, B ;
Lamas, S ;
Melián, EM .
ENDOCRINOLOGY, 2001, 142 (11) :4852-4860
[9]   Native and oxidized low density lipoproteins oppositely modulate the effects of insulin-like growth factor I on VSMC [J].
González-Timón, B ;
González-Muñoz, M ;
Zaragoza, C ;
Lamas, S ;
Melián, EM .
CARDIOVASCULAR RESEARCH, 2004, 61 (02) :247-255
[10]  
HAYRY P, 1995, FASEB J, V9, P1336